Cardiovascular National Account Executive
Company | Amgen |
---|---|
Location | Detroit, MI, USA, Cleveland, OH, USA |
Salary | $Not Provided – $Not Provided |
Type | Full-Time |
Degrees | Bachelor’s, Master’s, PhD |
Experience Level | Senior, Expert or higher |
Requirements
- Doctorate degree AND 2 years of Sales and/or Account Management experience
- Master’s degree AND 4 years of Sales and/or Account Management experience
- Bachelor’s degree AND 6 years of Sales and/or Account Management experience
Responsibilities
- Engage with executive decision-makers (e.g., CMOs, Chief Pharmacy Officers, Population Health leaders) to co-develop scalable initiatives that address care gaps and elevate cardiometabolic performance across the continuum.
- Lead the development and execution of national account strategies, aligned with the health system’s clinical, financial, operational and strategic goals.
- Help define what ‘great’ looks like by shaping this new capability in real-time, bringing bold ideas, cross-functional leadership, and customer insight into every engagement.
- Serve as the connective tissue between field teams, account-based marketing, health system medical affairs, and health IT—ensuring a unified and system-relevant approach.
- Translate science and strategy into action by unlocking system wide initiatives across care settings—from primary care to cardiology subspecialties.
- Bring the voice of the customer back to Amgen, helping evolve how we design, communicate, and deliver value to our most complex partners.
Preferred Qualifications
- 6 or more years of account management and/or commercial leadership experience strongly preferred
- 8 or more years of healthcare sales and/or marketing experience or related experience in buying processes and decision making
- District Manager experience preferred
- Knowledge of top IDN and health system’s structure, protocols, clinical and operations staff roles and responsibilities
- Knowledge of macro-level trends in the external healthcare environment that are influencing IDN and health system clinical and investment decisions